Epigenetic protein complexes: the adequate candidates for the use of a new generation of epidrugs in personalized and precision medicine in cancer - Archive ouverte HAL Access content directly
Journal Articles Epigenomics Year : 2019

Epigenetic protein complexes: the adequate candidates for the use of a new generation of epidrugs in personalized and precision medicine in cancer

(1, 2, 3, 4) , (5) , (6)
1
2
3
4
5
6

Abstract

Until recently, drug development in oncology was focused on treating most patients for a specific cancer type without taking in account the heterogeneity between these patients in term of response to treatment. Therefore, this type of broad treatment approach excludes the treatment of patient not responding to disease-specific common drugs. In this review, we focus on the different types of epigenetic drugs currently used as DNA methylation inhibitor agents and their limits in patient care due to their lack of specificity. We also highlight the emergence of a new type of epidrug with higher target specificity due to their original mechanism of action: the disruption of protein complexes involved in the epigenetic modifications.
Embargoed file
Embargoed file
Ne sera jamais visible
Loading...

Dates and versions

inserm-02484714 , version 1 (19-02-2020)

Identifiers

Cite

Pierre-Francois Cartron, Mathilde Cheray, Laurent Bretaudeau. Epigenetic protein complexes: the adequate candidates for the use of a new generation of epidrugs in personalized and precision medicine in cancer. Epigenomics, 2019, 12 (2), pp.171-177. ⟨10.2217/epi-2019-0169⟩. ⟨inserm-02484714⟩
56 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More